Events

Webinar on demand

Biopharma BD meets AI

Watch this insightful webinar with Alok Tayi, PhD, Co-Founder and CEO of Vibe Bio, on how AI is accelerating the business development process, helping executive teams move faster by making it easier to collect, manage, access, and evaluate drug assets, thus empowering them to conduct more thorough due diligence with the same resources.

Webinar on demand

Bottlenecks to breakthroughs: How AI is reshaping biopharma BD&L

Biopharma BD&L and search & evaluation teams are the front lines to identifying and advancing new assets and platforms that shape a company’s pipeline. Their work is diverse: from competitive benchmarking and program assessment to commercial forecasting, all while tracking the explosion of global pharmaceutical innovation.

Additional resources

Navigating pharma strategy and portfolio prioritization: A Q&A

June 19, 2025

With capital markets in flux, regulatory headwinds, and scientific risks, boards and executives must navigate pharma strategy and portfolio prioritization questions head-on.

The science of drug development: Lessons from a pioneer in pharmaceutical decision-making

May 5, 2025

Jay Andersen, a pioneer in pharmaceutical decision-making, shared some lessons learned from developing portfolio management and probability assessment approaches.

Orphan Therapeutics Accelerator Announces Foundational Partnerships

April 23, 2025

Founding Members Chiesi, BIAL Lead Initial Funding; Landmark Bio, Uncommon Cures Join Clinical Development Network; DVLP Medicines, Vibe Bio to Provide Integrated AI-based Solutions

Biopharma BD&L: the tsunami is upon us

April 23, 2025

Pharma's business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company's future. As the biopharma industry navigates an increasingly complex marketplace, traditional approaches to identifying and evaluating potential drug candidates are showing signs of strain.

How to improve biopharma business development with AI-powered due diligence

April 7, 2025

Biopharma business development and scientific teams are under a lot of pressure to identify the next big program for their indication and strategy.

Pharma portfolio analytics in a gen AI world

March 20, 2025

I recently sat down with a Top 20 pharmaceutical company to discuss their goals and struggles for the year ahead and how pharma portfolio analytics fits in.

Uncover new possibilities with VibeOne

Learn how VibeOne can help you discover your next indication or identify high potential development opportunities in your portfolio.